查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1783712

全球羧甲基纖維素市場成長、規模和趨勢分析—劑型展望、分銷管道、地區、競爭策略和細分市場預測（至 2034 年）

Global Carglumic Acid Market Growth, Size, Trends Analysis - By Dosage Form, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 248 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年全球葡聚醣酸市場將達到 3.0994 億人，複合年成長率為 7.69%。

卡谷氨酸由N-麩胺酸生成，可活化尿素循環中的第一個酶，從而幫助氨的排放和解毒。此藥尤其適用於治療丙酸血症和甲基丙二酸血症等罕見疾病，這些疾病屬於體染色體隱性遺傳，通常需要終生藥物治療才能維持正常健康。

阻礙因素：卡谷氨酸的使用受到原料採購成本高、產品加工所需資金增加、卡谷氨酸治療相關副作用的限制。此外，研發成本的不斷增加以及藥物本身的高昂價格也推高了整體製造成本，導致消費者尋求替代品。

本報告調查了全球羧甲基纖維素鈉市場，並提供了市場概況、市場影響因素和市場機會分析、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局以及主要企業的概況。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場動態

  • 促進因素、阻礙因素、機會與挑戰分析

第5章：變數與展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 熱圖分析

第6章 競爭態勢

  • 製造地、銷售區域、產品類型分佈
  • 併購、合作、產品發布與合作

7. 全球羧甲基纖維素市場（以劑型）

  • 口溶錠
  • 分散片
  • 其他

8. 全球氨基甲酸市場（依分銷管道）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：全球氨基甲酸市場

  • 市場規模和市場佔有率

第 10 章全球氨基甲酸市場（按地區）

  • 亞太地區
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亞
    • 其他
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他

第11章：公司簡介

  • Apothecon Pharmaceuticals Pvt. Ltd
  • Recordati Rare Diseases Inc
  • Manus Aktteva Biopharma LLP
  • Dipharma Francis Srl
  • NURAY CHEMICALS
  • NOVITIUM PHARMA LLC
  • Suven Life Sciences Limited
  • Biophore India Pharmaceuticals Pvt Ltd
  • Rhyme Organics and Chemicals Ltd
  • Aktteva Biopharma LLP
  • 其他

第12章 結論

第13章簡稱表

第 14 章參考鏈接

簡介目錄
Product Code: HLCA25177

Carglumic Acid Market Introduction and Overview

According to SPER market research, 'Global Carglumic Acid Market Size- By Dosage Form, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Carglumic Acid Market is predicted to reach 309.94 million by 2034 with a CAGR of 7.69%.

Carglumic acid is formed from N-acetyl glutamate and aids in ammonia elimination and detoxification by activating the first enzyme in the urea cycle. This medicine is particularly useful in the treatment of rare disorders such as propionic academia and methyl-malonic academia, which are autosomal recessive and frequently necessitate lifetime medical therapy to preserve normal health.

Restraints: The use of carglumic acid has been restricted by the high cost of acquiring raw materials, the increased capital required for processing the finished product, and certain negative consequences linked to carglumic acid treatments. Furthermore, rising research and development costs, combined with the high cost of medicine, have increased the cost of overall production, prompting customers to seek alternatives.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Dosage Form, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Apothecon Pharmaceuticals Pvt. Ltd, Recordati Rare Diseases Inc, Manus Aktteva Biopharma LLP, Dipharma Francis S.r.l, NURAY CHEMICALS, NOVITIUM PHARMA LLC, Suven Life Sciences Limited, Biophore India Pharmaceuticals Pvt Ltd, Rhyme Organics and Chemicals Ltd, Aktteva Biopharma LLP.

Global Carglumic Acid Market Segmentation:

By Dosage Form: Based on the Dosage Form, Global Carglumic Acid Market is segmented as; Orally Disintegrating Tablets, Dispersible Tablets.

By Distribution Channel: Based on the Distribution Channel, Global Carglumic Acid Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1.Introduction

  • 1.1.Scope of the report
  • 1.2.Market segment analysis

2.Research Methodology

  • 2.1.Research data source
    • 2.1.1.Secondary Data
    • 2.1.2.Primary Data
    • 2.1.3.SPER's internal database
    • 2.1.4.Premium insight from KOL's
  • 2.2.Market size estimation
    • 2.2.1.Top-down and Bottom-up approach
  • 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

  • 4.1.Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1.Drivers
    • 4.1.2.Restraints
    • 4.1.3.Opportunities
    • 4.1.4.Challenges

5.Market variable and outlook

  • 5.1.SWOT Analysis
    • 5.1.1.Strengths
    • 5.1.2.Weaknesses
    • 5.1.3.Opportunities
    • 5.1.4.Threats
  • 5.2.PESTEL Analysis
    • 5.2.1.Political Landscape
    • 5.2.2.Economic Landscape
    • 5.2.3.Social Landscape
    • 5.2.4.Technological Landscape
    • 5.2.5.Environmental Landscape
    • 5.2.6.Legal Landscape
  • 5.3.PORTER's Five Forces
    • 5.3.1.Bargaining power of suppliers
    • 5.3.2.Bargaining power of buyers
    • 5.3.3.Threat of Substitute
    • 5.3.4.Threat of new entrant
    • 5.3.5.Competitive rivalry
  • 5.4.Heat Map Analysis

6.Competitive Landscape

  • 6.1.Global Carglumic Acid Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Carglumic Acid Market

7.Global Carglumic Acid Market, By Dosage Form (USD Million) 2021-2034

  • 7.1.Orally Disintegrating Tablets
  • 7.2.Dispersible Tablets
  • 7.3.Others

8.Global Carglumic Acid Market, By Distribution Channel (USD Million) 2021-2034

  • 8.1.Hospital Pharmacies
  • 8.2.Retail Pharmacies
  • 8.3.Online Pharmacies

9.Global Carglumic Acid Market, (USD Million) 2021-2034

  • 9.1.Global Carglumic Acid Market Size and Market Share

10.Global Carglumic Acid Market, By Region, (USD Million) 2021-2034

  • 10.1.Asia-Pacific
    • 10.1.1.Australia
    • 10.1.2.China
    • 10.1.3.India
    • 10.1.4.Japan
    • 10.1.5.South Korea
    • 10.1.6.Rest of Asia-Pacific
  • 10.2.Europe
    • 10.2.1.France
    • 10.2.2.Germany
    • 10.2.3.Italy
    • 10.2.4.Spain
    • 10.2.5.United Kingdom
    • 10.2.6.Rest of Europe
  • 10.3.Middle East and Africa
    • 10.3.1.Kingdom of Saudi Arabia
    • 10.3.2.United Arab Emirates
    • 10.3.3.Qatar
    • 10.3.4.South Africa
    • 10.3.5.Egypt
    • 10.3.6.Morocco
    • 10.3.7.Nigeria
    • 10.3.8.Rest of Middle-East and Africa
  • 10.4.North America
    • 10.4.1.Canada
    • 10.4.2.Mexico
    • 10.4.3.United States
  • 10.5.Latin America
    • 10.5.1.Argentina
    • 10.5.2.Brazil
    • 10.5.3.Rest of Latin America

11.Company Profile

  • 11.1.Apothecon Pharmaceuticals Pvt. Ltd
    • 11.1.1.Company details
    • 11.1.2.Financial outlook
    • 11.1.3.Product summary
    • 11.1.4.Recent developments
  • 11.2.Recordati Rare Diseases Inc
    • 11.2.1.Company details
    • 11.2.2.Financial outlook
    • 11.2.3.Product summary
    • 11.2.4.Recent developments
  • 11.3.Manus Aktteva Biopharma LLP
    • 11.3.1.Company details
    • 11.3.2.Financial outlook
    • 11.3.3.Product summary
    • 11.3.4.Recent developments
  • 11.4.Dipharma Francis S.r.l
    • 11.4.1.Company details
    • 11.4.2.Financial outlook
    • 11.4.3.Product summary
    • 11.4.4.Recent developments
  • 11.5.NURAY CHEMICALS
    • 11.5.1.Company details
    • 11.5.2.Financial outlook
    • 11.5.3.Product summary
    • 11.5.4.Recent developments
  • 11.6.NOVITIUM PHARMA LLC
    • 11.6.1.Company details
    • 11.6.2.Financial outlook
    • 11.6.3.Product summary
    • 11.6.4.Recent developments
  • 11.7.Suven Life Sciences Limited
    • 11.7.1.Company details
    • 11.7.2.Financial outlook
    • 11.7.3.Product summary
    • 11.7.4.Recent developments
  • 11.8.Biophore India Pharmaceuticals Pvt Ltd
    • 11.8.1.Company details
    • 11.8.2.Financial outlook
    • 11.8.3.Product summary
    • 11.8.4.Recent developments
  • 11.9.Rhyme Organics and Chemicals Ltd
    • 11.9.1.Company details
    • 11.9.2.Financial outlook
    • 11.9.3.Product summary
    • 11.9.4.Recent developments
  • 11.10.Aktteva Biopharma LLP
    • 11.10.1.Company details
    • 11.10.2.Financial outlook
    • 11.10.3.Product summary
    • 11.10.4.Recent developments
  • 11.11.Others

12.Conclusion

13.List of Abbreviations

14.Reference Links